Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Mehdi El Amrani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9744-7826; OpenAlex author ID A5066196909. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
45
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 4 papers

Papers 9

  1. Nationwide analysis of one-year mortality following pancreatectomy in 17,183 patients with pancreatic cancer. Last author DOI 10.1016/j.hpb.2024.10.011↗
  2. End-of-life care for patients with pancreatic cancer in France: a nationwide population-based cohort study. Co-author DOI 10.1177/17588359251320731↗
  3. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  4. Influence of pre-operative sarcopenia on post-operative hepatic steatosis after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.21037/jgo-24-700↗
  5. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study. Last author DOI 10.1186/s12957-024-03393-7↗
  6. Impact on survival of sarcopenia, systemic inflammatory response and anthropometric factors after pancreatectomy for resectable pancreatic adenocarcinoma. Last author DOI 10.1186/s12957-024-03510-6↗
  7. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  8. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. First author DOI 10.3390/cancers12123866↗
  9. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Co-author DOI 10.1002/mc.23090↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stéphanie Truant · 7 shared papers, 2019–2025 · strength 1.29
  2. Ugo Marchèse · 3 shared papers, 2025 · strength 0.62
  3. Kaja Balcer · 2 shared papers, 2024–2025 · strength 0.48
  4. Anthony Turpin · 3 shared papers, 2020–2024 · strength 0.47
  5. Laurent Boyer · 2 shared papers, 2025 · strength 0.46
  6. Jonathan Garnier · 2 shared papers, 2024–2025 · strength 0.39
  7. Alexandre Doussot · 2 shared papers, 2022–2025 · strength 0.26
  8. Louis Caputo · 1 shared paper, 2025 · strength 0.26
  9. Lilian Schwarz · 2 shared papers, 2020–2022 · strength 0.24
  10. Anna Pellat · 1 shared paper, 2025 · strength 0.23
  11. Charles Poiraud · 1 shared paper, 2024 · strength 0.23
  12. Olivıer Turrini · 1 shared paper, 2024 · strength 0.23
  13. Lilian Schwartz · 1 shared paper, 2025 · strength 0.16
  14. Julie Navez · 1 shared paper, 2025 · strength 0.16
  15. Charles de Ponthaud · 1 shared paper, 2025 · strength 0.16
  16. Pierre‐Emmanuel Colombo · 1 shared paper, 2025 · strength 0.16
  17. Sébastien Gaujoux · 1 shared paper, 2025 · strength 0.16
  18. Francois-Regis Souche · 1 shared paper, 2025 · strength 0.16
  19. Emmanuel Buc · 1 shared paper, 2025 · strength 0.16
  20. Olivier Facy · 1 shared paper, 2025 · strength 0.16
  21. Alain Sauvanet · 1 shared paper, 2025 · strength 0.16
  22. Pietro Addeo · 1 shared paper, 2025 · strength 0.16
  23. Philippe Bachellier · 1 shared paper, 2025 · strength 0.16
  24. Mickaël Lesurtel · 1 shared paper, 2025 · strength 0.16
  25. Milena Muzzolini · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.